Biopharmaceutical company Faron Pharmaceuticals Ltd (AIM:FARN) (First North:FARON) on Wednesday announced positive interim Phase 2 results from its BEXMAB trial in myelodysplastic syndrome (MDS) patients who have failed a hypomethylating agent (HMA), also known as relapsed/refractory MDS (r/r MDS).

The interim results confirm earlier positive findings from Phases 1 and 2, demonstrating a high objective response rate (ORR) of 80% in 20 HMA-failed MDS patients. The estimated median overall survival (mOS) for these patients is approximately 13.4 months, significantly exceeding the 5-6 months typically expected under standard of care.

The BEXMAB treatment has been well-tolerated, with no dose-limiting toxicity. Full analysis of the data will be presented at the 66th American Society of Hematology (ASH) Annual Meeting on 9 December 2024.